Please login to the form below

Not currently logged in
Email:
Password:

basal insulin

This page shows the latest basal insulin news and features for those working in and with pharma, biotech and healthcare.

Sanofi reveals positive phase 3 results for long-acting insulin Toujeo

Sanofi reveals positive phase 3 results for long-acting insulin Toujeo

has compared it to Lantus (insulin glargine 100 units/mL), which lost its patent last year. ... The drug, Zynquista (sotagliflozin), was a key element in Sanofi’s plans to rebuild its diabetes franchise following the loss of patent protection for its

Latest news

  • Sanofi exits Zynquista alliance with Lexicon Sanofi exits Zynquista alliance with Lexicon

    The Sanofi/Lexicon partnered drug for type 1 diabetes was being co-developed as an add-on therapy to insulin injections to help improve blood sugar control. ... Zynquista was a key element in Sanofi’s plans to rebuild its diabetes franchise following

  • Success for AZ, setback for Sanofi in type 1 diabetes Success for AZ, setback for Sanofi in type 1 diabetes

    There is a broad array of insulin products on the market, including short-acting versions used after meals and long-acting (basal) insulins designed to give background control of blood glucose, ... The decision is a blow to Sanofi’s hopes of rebuilding

  • FDA adcomm split on Sanofi’s type 1 diabetes drug FDA adcomm split on Sanofi’s type 1 diabetes drug

    The panel voted eight to eight when asked if the overall benefits of Zynquista (sotagliflozin) outweighed its risks as an add-on to insulin treatment for adult patients with type 1 ... It is also a key element in Sanofi’s plans to rebuild its diabetes

  • FDA starts review of Sanofi’s oral type 1 diabetes drug FDA starts review of Sanofi’s oral type 1 diabetes drug

    Sotagliflozin – which has the proposed trade name Zynquista – has been developed as an add-on therapy to insulin injections to help improve blood sugar control in type 1, early-onset diabetes, ... for big-selling basal insulin Lantus (insulin glargine

  • CHMP recommends Teva's generic version of Astellas' Advagraf CHMP recommends Teva's generic version of Astellas' Advagraf

    This would allow its use in combination with basal insulin, where the therapy in use, together with diet and exercise, does not provide adequate glycaemic control.

More from news
Approximately 0 fully matching, plus 87 partially matching documents found.

Latest Intelligence

  • Harnessing commercial innovation Harnessing commercial innovation

    products - such as basal insulin Tresiba and its Ryzodeg and Xultophy combinations. ... We needed to ensure that people were safe. Then we needed to ensure that our insulin was made available to people in Japan.

  • Going the distance Going the distance

    The first of these came in February with the debut of Afrezza, the only inhaled insulin available in the US. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the new basal insulin that will be crucial to moving away from

  • Interview: Pierre Chancel, Sanofi Diabetes Interview: Pierre Chancel, Sanofi Diabetes

    ORBIT (Observational Registry for Basal Insulin Treatment) is a study focused on type 2 diabetes in China and the result of Sanofi's partnership with the CDS and George Institute for ... The company sees particular potential for Lyxumia as a combination

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics